AI SPACs and IPOs on the Move. PRST Warrants Offer Life-Changing Upside

Two months ago we wrote a blog about certain AI SPAC and IPO listings. Bullfrog AI Holdings, Inc. (BFRG), Presto Automation Inc. (PRST) and CXApp Inc. (CXAI). We suggested to buy their warrants, listed as BFRGW, PRSTW and CXAIW respectively. BFRG and BFRGW haven't done much since then. CXAI has been about flat, but CXAIW has gone on a great run from $0.14 to $0.55, resulting in substantial profits for buyers two months ago. 

As profits have already been taken on CXAIW and BFRG is quiet right now, what we want to focus on at this time is PRST and PRSTW. Despite the stock steadily moving up to $4.70 in two months, the warrants have remained in the $0.10 range. They expire in September 2027 so there is plenty of time left on them. These warrants have a strike price of $8.21 and it takes two warrants to exercise for one share. So for instance, if the stock price moves to $18.21, the warrants aren't worth $10, but $5. The warrants also have an early redemption call price of $16.50, where the company can reduce the time to expiry from 5 years to 30 days. This could create issues and downward pressure on the stock price, but $16.50 is a long way away and there would be a lot of upside from $0.10 in this scenario.

PRST has been on a steady rise, but remains a candidate to spike 100% or more at any time given its status as an AI hype stock and its small float of 22 million shares. The chart looks excellent as well, with it recently pushing through the MA50 resistance on the weekly chart:















If the stock continues its upward trajectory, expect the PRSTW warrants to suddenly catch on fire. It'll be like CXAIW where that set of warrants was stuck in the low $0.10's for a while then shot up 5x in a few weeks.

Comments

Post a Comment

Popular posts from this blog

Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale

Image
Heavily shorted Carvana Co. (CVNA) is in the middle of a squeeze. One that looks eerily similar to the beginnings of the one we saw on GME that eventually made it run to $400 and took down Melvin Capital. Once again certain market players or commentators who focus on fundamentals and who misunderstand or downplay the short squeeze thesis will only add fuel to the fire as they short the stock. Will Carvana be able to refinance its debts next year? Will it become profitable by then? Who knows, and who cares. 2024 isn't the timeline here. The timeline starts as early as June 16, 2023. Triple witching day on options. This time Kerrisdale Capital is the target. The firm is in a desperate spot because the last short call it made was C3.ai, Inc. (AI). AI is in the middle of its own short squeeze and has nearly doubled into $40's since Kerrisdale tried taking it down: The AI report is still featured alongside on the CVNA one on Kerrisdale's website , so we can assume this position
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by brokers to fund a com
Read more

CVNA Squeezing, ROOT and RXRX are Next

Image
Earlier today we stated that Root, Inc. (ROOT) and Recursion Pharmaceuticals, Inc. (RXRX) were next to squeeze after Carvana (CVNA). One month ago  we mentioned  the gamma squeeze potential on CVNA. Now that this is at hand and the stock has more than doubled, it's time to go long on two other heavily shorted stocks that stand to benefit from the CVNA squeeze as desperate shorts have to cover.  The strategy worked perfectly as ROOT increased 19% and RXRX increased 16% on the day while CVNA rose another 40%. This will be just the beginning as shorts are hemorrhaging on multiple related positions. If you look at the chart for the day, it becomes very clear how highly correlated these three stocks are right now. This is undeniably a sign that shorts, particularly algo HFT shorts are covering simultaneously held positions.  CVNA  made a $126 million investment  into ROOT and has embedded its insurance program into its systems. So any improvement in financial performance on CVNA implie
Read more